Health & WellnessTech
PROTXX
Wearable device that improves the lives of those with complex neurological conditions
Menlo Park,
CA
Investment type:
Equity
(Convertible Note)
Target raise:
$250,000
- $1,070,000
Minimum investment:
$100
$100
End date:
May 01, 2021
May 01, 2021
ended
Share
Highlights
- Invented 1 minute non-invasive test that identifies and quantifies neuromotor and neurosensory impairments
- PAAS model enhances management and treatment of concussions, stroke, Parkinson’s, multiple sclerosis
- Our solution is commercially available with over 20 customers and pilots in U.S., Canada, U.K., Japan
- We reduce time, travel, and costs for patients through remote patient monitoring
Our Story
PROTXX integrates wearable sensor and machine learning innovations to replace bulky and expensive clinical equipment and time-consuming testing procedures for neurological conditions in which patients suffer from impairments to multiple physiological systems. PROTXX solves the difficult problem of identifying and quantifying these impairments, enhancing patient care with easy-to-use, low-cost, in-clinic and remote patient assessments.
Our Ambition
Of the $800B in annual healthcare costs generated by neurodegenerative conditions in the U.S., over $100B arise from inefficiencies that can be reduced or eliminated using the PROTXX solution. The addressable annual revenue opportunity for PROTXX exceeds $12B, and our target is to be the leading global provider of these solutions and to secure the leading share of this market within 5 years. These projections cannot be guaranteed.